Will Gilead's twice-yearly injection dominate the HIV PrEP market? GSK doesn’t think so
The long-running HIV market rivalry between Gilead Sciences and GSK is about to turn a new page this year as Gilead looks to disrupt the pre-exposure prophylaxis field with a twice-yearly injection. But GSK, with a bimonthly option, doesn’t think its rival can hog the entire long-acting market.
The long-running HIV market rivalry between Gilead Sciences and GSK is about to turn a new page this year as Gilead looks to disrupt the pre-exposure prophylaxis field with a twice-yearly injection. But GSK, with a bimonthly option, doesn’t think its rival can hog the entire long-acting market.
